MENA Fabry Disease Treatment Market Size Expected to Reach USD 295.32 Million by 2034, Growing at a CAGR of 5.8%

MENA Fabry Disease Treatment Market

The MENA Fabry disease treatment market size was valued at USD 167.76 million in 2024. With a CAGR of 5.8% during 2025-2034, the market is projected to grow to USD 295.32 million by 2034.

Market Introduction

Fabry disease treatment focuses on addressing the underlying enzyme deficiency and managing the wide range of symptoms caused by this inherited lysosomal storage disorder. The disease occurs due to a deficiency or malfunction of the alpha-galactosidase A enzyme, which leads to the accumulation of a fatty substance called globotriaosylceramide (GL-3) within the body's cells. The cornerstone of treatment is enzyme replacement therapy (ERT). In ERT, patients receive regular infusions of a synthetic version of the missing enzyme to help clear GL-3 buildup and slow the progression of organ damage. Another option for certain patients with amenable gene mutations is chaperone therapy. Cheaperone therapy uses a small-molecule drug to stabilize and enhance the activity of the body's own faulty enzyme.

Download Free Sample PDF Copy of the Report:
https://www.polarismarketresearch.com/industry-analysis/middle-east-north-africa-mena-fabry-disease-treatment-market/request-for-sample

Market Key Players

The rising number of product launches and robust market expansion strategies shape the competitive landscape of the market. A few of the key MENA Fabry disease treatment market players include:

List of Key Companies with Approved Drugs:
Chiesi Farmaceutici S.p.A.
JCR Pharmaceuticals Co., Ltd.
Protalix BioTherapeutics Inc.
Sanofi
Takeda Pharmaceutical

List of Companies with Drugs Under Clinical Trial Phase:
Amicus Therapeutics, Inc.
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd.
ISU ABXIS Co., Ltd.
Sangamo Therapeutics, Inc.

Request for a Discount on this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/middle-east-north-africa-mena-fabry-disease-treatment-market/request-for-discount-pricing

Market Dynamics

Improved Genetic Testing Infrastructure: Investments in additional diagnostic facilities across the MENA are expanding access to advanced genetic testing for rare diseases, such as Fabry. Several governments are prioritizing early detection by equipping labs and hospitals with the capability to perform precise gene analysis. Collaborations between regional health authorities and global health firms help streamline the transfer of technology and training for local professionals.

Growth in Health Insurance Penetration: There has been a notable expansion of healthcare insurance across major MENA economies, including Qatar, the UAE, and Saudi Arabia. For instance, the 2024 Healthcare Statistics for Saudi Arabia, published by the General Authority for Statistics, indicated that 100% of Saudi citizens had healthcare coverage. Public and private insurers are increasingly offering reimbursement for high-cost treatments. This shift has made treatment increasingly accessible for patients who can't bear the financial burden. Thus, the growth in health insurance penetration is contributing to the development of the MENA Fabry disease treatment market.

Click here to Access the Full Report:
https://www.polarismarketresearch.com/industry-analysis/middle-east-north-africa-mena-fabry-disease-treatment-market

Market Segmentation

The market is primarily segmented based on route of administration, therapy, and distribution channel.

Based on route of administration, the intravenous route segment led the market in 2024. The segment's dominance is primarily attributed to the established use of ERT, which requires infusion-based therapy. Hospitals and specialty clinics in the region are increasingly equipped to administer IV treatments, offering controlled environments and trained staff to manage infusion protocols.

By therapy, the substrate reduction therapy segment is projected to register a significant CAGR from 2025 to 2034. The segment's robust growth is driven by increasing clinical adoption and rising patient preference for oral treatment regimens. In addition, rising physician awareness of substitute therapy has led to more personalized treatment strategies that integrate SRT where appropriate.

By Route of Administration Outlook (Revenue USD Million, 2020-2034)
Intravenous Route
Oral Route

By Therapy Outlook (Revenue USD Million, 2020-2034)
Enzyme Replacement Therapy (ERT)
Substrate Reduction Therapy (SRT)
Others

By Distribution Channel Outlook (Revenue USD Million, 2020-2034)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Buy Now:
https://www.polarismarketresearch.com/buy/4772/0

Regional Assessment:

The MENA Fabry Disease Treatment Market is witnessing significant growth, led by strong country-specific developments. Saudi Arabia holds a dominant 31% share, driven by Vision 2030 healthcare reforms and enhanced genetic screening. Egypt is emerging as a high-growth market with a projected CAGR of 6.2%, supported by public-private partnerships and increased diagnostics capacity. Turkey's market, valued at USD 34 million in 2024, benefits from expanded access to orphan drugs, regulatory support, and early screening initiatives. These nations are improving patient access to enzyme replacement therapies through hospital upgrades, insurance expansion, and international collaborations, collectively advancing rare disease treatment across the region.

By Country Outlook (Revenue USD Million, 2020-2034)

Saudi Arabia
Turkey
Iran
Egypt
Algeria
Morocco
Iraq
Libya
Rest of MENA

More Trending Latest Reports by Polaris Market Research:

Biotechnology Market
https://www.polarismarketresearch.com/industry-analysis/biotechnology-market

E-Pharmacy Market
https://www.polarismarketresearch.com/industry-analysis/e-pharma-market

Cell Culture Market
https://www.polarismarketresearch.com/industry-analysis/cell-culture-market

Virus Filtration Market
https://www.polarismarketresearch.com/industry-analysis/virus-filtration-market

Viscosupplementation Market
https://www.polarismarketresearch.com/industry-analysis/viscosupplement-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers

This release was published on openPR.